From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
Insulin (swine) is an orally active insulin derived from pigs. Insulin (swine) when administered orally acts as an antigen to reduce the severity of pancreatic lymphocyte infiltration, but has no metabolic effect on blood glucose levels. Insulin (swine) increases glucose oxidation, stimulates lipogenesis, and lowers blood glucose levels. Insulin (swine) can be used in diabetes research .
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFB Antibody (CSL346) is a CHO-expressed human antibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 196.34 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca 2+-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a molecular weight (MW) of 144.70 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Pyr-Pro-Arg-pNA (S2366) hydrochloride is a chromogenic peptide substrate for Factor XI and Activated protein C (APC). Pyr-Pro-Arg-pNA hydrochloride can induce noncompetitive inhibition of factor XI activation through occupancy of the active site of the factor XIa-light chain. Pyr-Pro-Arg-pNA hydrochloride can be used for measurement of APC amidolytic activity .
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ROCK2-IN-8 (Compound 1) is an orally active ROCK2 inhibitor, with an IC50 of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .
DCBY02 is a monoclonal antibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-EphB2 Antibody is a CHO expressed human antibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 lambda, Isotype Control (HY-P991206).
smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
ME-3407 (EF-4040) is a H +-K +-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H +-K +-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer .
ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury .
Tofersen-d27 (BIIB067-d27) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.
CZEN-002 is a derivative of alpha-melanocyte-stimulating hormone that has anti-inflammatory and antibacterial properties, inhibiting the production of TNF-α .
Anflekitug is a CHO-expressed human antibody that targets IL-1β. Anflekitug has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anflekitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Pyr-Pro-Arg-pNA (S2366) is a chromogenic peptide substrate for Factor XI and Activated protein C (APC). Pyr-Pro-Arg-pNA can induce noncompetitive inhibition of factor XI activation through occupancy of the active site of the factor XIa-light chain. Pyr-Pro-Arg-pNA can be used for measurement of APC amidolytic activity .
A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
TachypleginA-2 is a small-molecule inhibitor of parasite motility and invasion. TachypleginA-2 reproducibly induces the TgMLC1 (an essential light chain) mobility shift .
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
F 991 is an immunoglobulin free light chain antagonist. F 991 can significantly reduce the levels of pro-inflammatory cytokines (TNF-α and IL-6). F 991 can be used for research on allergic conditions .
PPO-allene is a covalent botulinum neurotoxin (BoNT) light chain inhibitor (IC50: 20.9 μM). PPO-allene (0.3 mg/kg, i.v.) demonstrates an in vivo half-life of approximately 1.5 h in mice .
SIRT-IN-5 is a SIRT3 inhibitor, with an IC50 value of 2.88 μM. SIRT-IN-5 can promote the differentiation of multiple myeloma cells, along with an increase in the expression of the differentiation antigen CD49e and human immunoglobulin light chains λ and κ .
Anti-CLEC4C Antibody is a CHO-expressed humanized antibody that targets CLEC4C. The Anti-CLEC4C Antibody carries a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 150 kDa.
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
Vasigrobart is a CHO-expressed human antibody that targets PDGFB. Vasigrobart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Vasigrobart can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .
Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins .
LC kinetic stabilizer-1 (compound 21) is a potent and selective amyloidogenic immunoglobulin light chain kinetic stabilizer with EC50s of 140 and 74.1 nM for WIL-FL * and WIL-FL * T46L/F49Y, respectively. WIL-FL is an amyloidogenic FL LC dimer .
Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CDP-484 is a CHO-expressed human antibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
R707 is a human antibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (C836) is a neutralizing monoclonal antibody targeting human IL-13. The Fab fragment of Anti-IL-13 Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .
HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ABCB5 Antibody is a CHO-expressed human antibody that targets ABCB5. The Anti-ABCB5 Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ABCB5 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GOLM1 Antibody is a CHO-expressed human antibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-NOTCH1 Antibody is a CHO-expressed human antibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
ML-9 (Standard) is the analytical standard of ML-9 (HY-100932). This product is intended for research and analytical applications. ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
NA0359 is a derivative of SF2370 (HY-N6732). NA0359 inhibits the actin-myosin-ATP interaction in native smooth muscle actomyosin and myosin light chain phosphorylation .
Anti-GFRA4 Antibody (scFv) is a recombinant single-chain antibody fragment targeting GFRA4. Anti-GFRA4 Antibody (scFv) is formed by connecting the variable region of the heavy chain (VH) and the variable region of the light chain (VL) through a flexible short peptide (Linker), without the Fc segment, while maintaining the antigen-binding specificity.
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NSC-84096 is an endopeptidase activity inhibitor with the ability to inhibit the activity of botulinum neurotoxin type A light chain (rBoNT/A-LC). NSC-84096 is able to effectively inhibit the enzymatic activity of botulinum neurotoxin in vitro, indicating its potential in inhibiting botulism. The mechanism of action of NSC-84096 may provide hope for the development of small molecule compounds targeting these deadly toxins .
VB1-050 is a human antibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RAMP3 Antibody is a CHO expressed human antibody that targets RAMP3. The Anti-RAMP3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RAMP3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR7 Antibody is a CHO-expressed human antibody that targets TLR7. Anti-TLR7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TLR7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-MMP9 Antibody is a CHO-expressed human antibody that targets MMP9. The Anti-MMP9 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.76 kDa. For the isotype control of the Anti-MMP9 Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MUSK Antibody is a humanized antibody expressed in CHO that targets MUSK. The Anti-MUSK Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 143.86 kDa. For the isotype control of Anti-MUSK Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-STOP1 Antibody is a human antibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SERPINE1 Antibody is a human-derived antibody expressed in CHO, targeting SERPINE1. The Anti-SERPINE1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SERPINE1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-INHBB/Activin B Antibody is a human antibody expressed in CHO, targeting INHBB/Activin B. The Anti-INHBB/Activin B Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-INHBB/Activin B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively .
Anti-LIF Antibody (MSC-1) is a CHO-expressed human antibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPSAB1 Antibody is a CHO-expressed human antibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .
Anti-PACAP38 Antibody is a human antibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .
Asedebart is a CHO-expressed human antibody that targets Adrenocorticotropic hormone (ACTH). Asedebart blocks the binding of ACTH to its receptor through antagonism. Asedebart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Asedebart can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Asedebart can be used for inflammatory diseases such as psoriasis and ulcerative colitis research .
Stellettamide A TFA is a marine toxin found in a marine sponge. Stellettamide A TFA is a calmodulin inhibitor. Stellettamide A TFA can inhibit Ca 2+/Mg 2+ ATPase, phosphodiesterase, myosin light chain , and Mg 2+-ATPase. Stellettamide A TFA inhibits high K +- and Ca 2+-induced contraction in permeabilized smooth muscle. Stellettamide A TFA exhibits antifungal activity against Mortierella remannianus. Stellettamide A TFA can be used for the research of fungal infection .
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Hepcidin/HAMP Antibody (LY2787106) is a CHO-expressed human antibody that targets Hepcidin/HAMP.Anti-Hepcidin/HAMP Antibody (LY2787106) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody (LY2787106) can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PTPRC/CD45 Antibody is a CHO-expressed human antibody that targets PTPRC/CD45. Anti-PTPRC/CD45 Antibody has a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PTPRC/CD45 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL4 Antibody is a CHO expressed human antibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed human antibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL8 Antibody is a CHO expressed human antibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Adakitug exhibits anti-tumor activity and can be applied in tumor research .
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC50s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch .
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR20 Antibody (DS-6157 antibody) is a human antibody expressed in CHO, targeting GPR20. Anti-GPR20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.62 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor. After being orally administered at a dose of 50 mg/kg in a mouse model, it can reduce the level of plasma neurofilament light chain (NfL). SARM1-IN-4 prevents programmed axonal degeneration by inhibiting the NAD+ hydrolase activity of SARM1, and it can be used in research related to neurodegenerative diseases and neurological disorders (such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies, etc.).
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TNFSF2/TNFa Antibody is a CHO-expressed human antibody that targets TNFSF2/TNFa. The Anti-TNFSF2/TNFa Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TNFSF2/TNFa Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MSPR/RON/CD136 Antibody is a human antibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ACVR2B Antibody is a human antibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CHI3L1 Antibody is a human antibody expressed in CHO that targets CHI3L1. The Anti-CHI3L1 Antibody contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CHI3L1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Rattusin is an antimicrobial peptide. Rattusin exerts bactericidal activity by damaging membrane integrity. Rattusin can be used for antimicrobial research .
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR73/PROKR1 Antibody is a CHO-expressed human antibody that targets GPR73/PROKR1. Anti-GPR73/PROKR1 Antibody features a huIgG4SP heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR73/PROKR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ICAM3/CD50 Antibody is a human antibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFSF2/TNFa Antibody (hMAK195) is a human antibody expressed in CHO cells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed human antibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
Anti-ANO1/TMEM16A Antibody is a CHO-expressed human antibody that targets ANO1/TMEM16A. The Anti-ANO1/TMEM16A Antibody consists of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-ANO1/TMEM16A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CEACAM1/CD66a Antibody is a human antibody expressed in CHO cells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed human antibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
Anti-DDR1/CD167a Antibody is a CHO-expressed antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a mouse IgG1 type heavy chain and a mouse κ type light chain, with a predicted molecular weight (MW) of 143.32 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
W-7 (hydrochloride) (Standard) is the analytical standard of W-7 (hydrochloride) (HY-100912). This product is intended for research and analytical applications. W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .
Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of ADCs .
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHO cells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed human antibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed human antibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL12/SDF1a Antibody is a CHO-expressed human antibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease .
FP802 is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS). FP802 can be used for AD and ALS research .
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-CDCP1/CD318 Antibody (38 E11) is a CHO-expressed human antibody targeting CDCP1/CD318. The Anti-CDCP1/CD318 Antibody (38 E11) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CDCP1/CD318 Antibody (38 E11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Pseudo RACK1, a peptide, is a PKC agonist with homologous sequences of PKC. Pseudo RACK1 interacts selectively with β-PKC at an autoregulatory site (RACK-binding site) and activates it in the absence of PKC activators, following inducing PKC-mediated histone phosphorylation .
FP802 dihydrochloride is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 dihydrochloride exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 dihydrochloride stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS) . FP802 dihydrochloride can be used for AD and ALS research .
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a CHO-expressed human antibody targeting F3/Factor III/Tissue Factor/CD142. The Anti-F3/Factor III/Tissue Factor/CD142 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-F3/Factor III/Tissue Factor/CD142 Antibody can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
DfTat is a dimer of the prototypical cell-penetrating peptide TAT. DfTat can deliver small molecules, peptides and proteins into live cells with a particularly high efficiency. DfTat labeled with the rhodamine can be used as a tracer for easy detection .
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
Insulin (swine) is an orally active insulin derived from pigs. Insulin (swine) when administered orally acts as an antigen to reduce the severity of pancreatic lymphocyte infiltration, but has no metabolic effect on blood glucose levels. Insulin (swine) increases glucose oxidation, stimulates lipogenesis, and lowers blood glucose levels. Insulin (swine) can be used in diabetes research .
MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca 2+-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .
DfTat is a dimer of the prototypical cell-penetrating peptide TAT. DfTat can deliver small molecules, peptides and proteins into live cells with a particularly high efficiency. DfTat labeled with the rhodamine can be used as a tracer for easy detection .
Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca 2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer .
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .
CZEN-002 is a derivative of alpha-melanocyte-stimulating hormone that has anti-inflammatory and antibacterial properties, inhibiting the production of TNF-α .
A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
F 991 is an immunoglobulin free light chain antagonist. F 991 can significantly reduce the levels of pro-inflammatory cytokines (TNF-α and IL-6). F 991 can be used for research on allergic conditions .
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins .
Pseudo RACK1, a peptide, is a PKC agonist with homologous sequences of PKC. Pseudo RACK1 interacts selectively with β-PKC at an autoregulatory site (RACK-binding site) and activates it in the absence of PKC activators, following inducing PKC-mediated histone phosphorylation .
MLCK Peptide, control is a myosin light-chain
kinase. Adding MLCK peptide to permeabilized L15 cells dramatically decreased
IICR. MLCK peptide caused a reduction in the extent of IICR with no change in
the affinity of IP3 for the IP3R .
Rattusin is an antimicrobial peptide. Rattusin exerts bactericidal activity by damaging membrane integrity. Rattusin can be used for antimicrobial research .
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
MCE Protein L Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein L, effectively purifies mammalian monoclonal and polyclonal antibodies which have kappa light chain.
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFB Antibody (CSL346) is a CHO-expressed human antibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD5 Antibody is a human-derived antibody expressed in CHO, targeting CD5. Anti-CD5 Antibody contains huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145.05 kDa.
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
NGM-120 is a CHO-expressed human antibody that targets GFRAL. NGM-120 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.7 kDa. The isotype control for NGM-120 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 196.34 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a molecular weight (MW) of 144.70 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NGM-313 is a CHO-expressed human antibody targeting Klotho Beta. NGM-313 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for NGM-313 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AMG-811 is a CHO expressed human antibody that targets IFNg. AMG-811 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for AMG-811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NGM-621 is a CHO-expressed human antibody that targets Complement C3. NGM-621 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.04 kDa. The isotype control for NGM-621 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
PY159 is a humanized antibody expressed in CHO cells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
DCBY02 is a monoclonal antibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
ASK-8007 is a humanized antibody expressed by CHO, targeting Osteopontin. ASK-8007 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for ASK-8007 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-570 is a humanized antibody expressed in CHO that targets ICOS/CD278. MEDI-570 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-570 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NTX-1088 is a CHO-expressed humanized antibody that targets PVR/CD155. NTX-1088 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.86 kDa. The isotype control for NTX-1088 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ATN-658 is a mouse-derived IgG antibody expressed in CHO cells that targets PLAUR/uPAR/CD87. ATN-658 contains muIgG1 heavy chain and mκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for ATN-658 can be referenced as Mouse IgG1 kappa, Isotype Control (HY-P99977).
The Anti-EphB2 Antibody is a CHO expressed human antibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology .
Anti-CXADR Antibody is a humanized antibody expressed in CHO, targeting CXADR. The Anti-CXADR Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXADR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Ibritumomab is a mouse antibody expressed in CHO, targeting CD20/MS4A1. Ibritumomab is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Ibritumomab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MVT-5873 is a humanized antibody expressed in CHO cells, targeting Sialyl-Lewis A. MVT-5873 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for MVT-5873 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Albumin Antibody is a human-derived antibody expressed in CHO cells, targeting Albumin. The Anti-Albumin Antibody features huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 144.24 kDa. The isotype control for Anti-Albumin Antibody can refer to Human IgG1 lambda2, Isotype Control (HY-P990096).
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 lambda, Isotype Control (HY-P991206).
The Anti-TPBG Antibody (PF-06263507) is a humanized antibody expressed in CHO cells that targets TPBG. PF-06263507 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for PF-06263507 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Selcodebart (Anti-RGMC/HFE2 Antibody (DISC-0974)) is a CHO-expressed human antibody that targets RGMC/HFE2. Selcodebart features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.66 kDa. For the isotype control of Selcodebart, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anflekitug is a CHO-expressed human antibody that targets IL-1β. Anflekitug has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anflekitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
KHK-2898 is a humanized antibody expressed in CHO targeting CD98. KHK-2898 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for KHK-2898 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Meflin Antibody is a humanized antibody expressed in CHO cells, targeting Meflin. The Anti-Meflin Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Meflin Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) is an anti-mouse Kappa Immunoglobulin Light Chain IgG1 monoclonal antibody. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can reduce the phosphorylation levels of Src and Syk in B cells and the antigen presentation ability of B cells. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can be used for research on immunology .
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
Anti-CLEC4C Antibody is a CHO-expressed humanized antibody that targets CLEC4C. The Anti-CLEC4C Antibody carries a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 150 kDa.
Vasigrobart is a CHO-expressed human antibody that targets PDGFB. Vasigrobart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Vasigrobart can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .
Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Apamistamab is a CHO-expressed human antibody that targets PTPRC/CD45. Apamistamab carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.52 kDa. The isotype control for Apamistamab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-ERG Antibody is a humanized antibody expressed in CHO, targeting ERG. The Anti-ERG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ERG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ATH3G10 is a humanized antibody expressed in CHO that targets Phosphorylcholine. ATH3G10 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for ATH3G10 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
RGX-019 is a humanized antibody expressed in CHO cells, targeting MER/MERTK. RGX-019 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for RGX-019 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CDP-484 is a CHO-expressed human antibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
BMS-986021 (BMS-986148 antibody) is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
R707 is a human antibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Hersintuzumab is a CHO-expressed humanized antibody targeting ERBB2/HER2/CD340. Hersintuzumab is equipped with a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Hersintuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (C836) is a neutralizing monoclonal antibody targeting human IL-13. The Fab fragment of Anti-IL-13 Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .
HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ABCB5 Antibody is a CHO-expressed human antibody that targets ABCB5. The Anti-ABCB5 Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ABCB5 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GOLM1 Antibody is a CHO-expressed human antibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
LY2525623 is a humanized antibody expressed in CHO targeting IL-23. LY2525623 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for LY2525623 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-578 is a CHO-expressed human antibody that targets NGF/bNGF. MEDI-578 has a huIgG2a heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-578 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Haptoglobin Antibody is a humanized antibody expressed in CHO cells that targets Haptoglobin. The Anti-Haptoglobin Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Haptoglobin Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GFRA4 Antibody (scFv) is a recombinant single-chain antibody fragment targeting GFRA4. Anti-GFRA4 Antibody (scFv) is formed by connecting the variable region of the heavy chain (VH) and the variable region of the light chain (VL) through a flexible short peptide (Linker), without the Fc segment, while maintaining the antigen-binding specificity.
RG-7652 is a humanized antibody expressed in CHO cells, targeting PCSK9. RG-7652 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.88 kDa. The isotype control for RG-7652 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Polyubiquitin Antibody is a human-derived antibody expressed in CHO, targeting Polyubiquitin. The Anti-Polyubiquitin Antibody carries huIgG1 type heavy chains and huκ type light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Polyubiquitin Antibody can be referenced with Human IgG1 kappa, Isotype Control (HY-P99001).
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CMAB008 is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. CMAB008 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CMAB008 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-PCLA Antibody is a recombinant human antibody expressed in CHO cells, targeting PCLA. The Anti-PCLA Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-PCLA Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-PMEL Antibody is a human-derived antibody expressed in CHO cells, targeting PMEL. The Anti-PMEL Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.54 kDa. The isotype control for the Anti-PMEL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
IMMU-114 is a CHO expressed humanized antibody that targets HLA-DR. IMMU-114 is composed of huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.1 kDa. The isotype control for IMMU-114 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
TOL-101 is a humanized antibody expressed in CHO cells that targets TCR. TOL-101 is composed of huIgG2 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 125.6 kDa. The isotype control for TOL-101 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-ALP Antibody is a CHO-expressed human antibody that targets ALP. The Anti-ALP Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 148.04 kDa. For isotype controls of the Anti-ALP Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Citatuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Citatuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.4 kDa. The isotype control for Citatuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ELB-031 is a humanized antibody expressed in CHO, targeting TYRO3. ELB-031 contains a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 143.64 kDa. The isotype control for ELB-031 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-c-RET Antibody is a CHO-expressed human antibody that targets c-RET. The Anti-c-RET Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-c-RET Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PDGFC/VEGFE Antibody is a CHO-expressed human antibody that targets PDGFC/VEGFE. Anti-PDGFC/VEGFE Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDGFC/VEGFE Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-DLL4 Antibody is a CHO-expressed human antibody targeting DLL4. The Anti-DLL4 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-DLL4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-NOTCH3 Antibody is a CHO-expressed human antibody that targets NOTCH3. The Anti-NOTCH3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-NOTCH3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ESBA-105 is a humanized antibody expressed in CHO cells, targeting TNFSF2/TNFa. ESBA-105 carries a huIgG1 heavy chain and a huκ light chain, with an anticipated molecular weight (MW) of 145.14 kDa. The isotype control for ESBA-105 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
PDL-241 is a humanized antibody expressed in CHO that targets SLAMF7/CS1. PDL-241 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.38 kDa. The isotype control for PDL-241 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TCR Antibody (NKTT320) is a humanized antibody expressed in CHO, targeting TCR. Anti-TCR Antibody (NKTT320) features huIgG4 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TCR Antibody (NKTT320) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-NOTCH1 Antibody is a CHO-expressed human antibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
GFB-024 is a CHO-expressed humanized antibody that targets CB1/CNR1. GFB-024 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GFB-024 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VB1-050 is a human antibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LY3022855 is a CHO-expressed human antibody that targets CSF1R/M-CSFR/CD115. LY3022855 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LY3022855 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ROBO1 Antibody is a CHO-expressed human antibody that targets ROBO1. The Anti-ROBO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ROBO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RAMP3 Antibody is a CHO expressed human antibody that targets RAMP3. The Anti-RAMP3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RAMP3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR7 Antibody is a CHO-expressed human antibody that targets TLR7. Anti-TLR7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TLR7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD151 Antibody is a CHO-expressed humanized antibody that targets CD151. The Anti-CD151 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CD151 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-TAT226 Antibody is a CHO-expressed humanized antibody targeting TAT226. The Anti-TAT226 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-TAT226 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MMP9 Antibody is a CHO-expressed human antibody that targets MMP9. The Anti-MMP9 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.76 kDa. For the isotype control of the Anti-MMP9 Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-PDGFB Antibody (MOR-8457) is a CHO-expressed human antibody that targets PDGFB. Anti-PDGFB Antibody (MOR-8457) is composed of a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PDGFB Antibody (MOR-8457) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IDO2 Antibody is a CHO-expressed human antibody that targets IDO2. Anti-IDO2 Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 151.06 kDa. The isotype control for Anti-IDO2 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
FG-3246 (FOR46) is a humanized antibody expressed in CHO cells that targets CD46. FG-3246 (FOR46) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for FG-3246 (FOR46) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
RG-6125 is a humanized antibody expressed in CHO, targeting CDH11/Cadherin-11. RG-6125 has a huIgG2 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for RG-6125 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MUSK Antibody is a humanized antibody expressed in CHO that targets MUSK. The Anti-MUSK Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 143.86 kDa. For the isotype control of Anti-MUSK Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-PAR2 Antibody is a human-derived antibody expressed in CHO cells, targeting PAR2. The Anti-PAR2 Antibody contains a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-PAR2 Antibody can be referred to as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-STOP1 Antibody is a human antibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
TTX-030 is a humanized antibody expressed in CHO cells, targeting ENTPD1/CD39. TTX-030 contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for TTX-030 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFR/c-Met Antibody is a humanized antibody expressed in CHO, targeting HGFR/c-Met. The Anti-HGFR/c-Met Antibody contains huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFR/c-Met Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD48 Antibody is a humanized antibody expressed in CHO cells that targets CD48. The Anti-CD48 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-CD48 Antibody, you can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Histone H4 Antibody is a CHO-expressed human antibody that targets Histone H4. Anti-Histone H4 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Histone H4 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KID3 Antibody is a CHO-expressed human antibody that targets KID3. The Anti-KID3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 147.04 kDa. The isotype control for Anti-KID3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD83 Antibody is a humanized antibody expressed in CHO cells that targets CD83. Anti-CD83 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.8 kDa. The isotype control for Anti-CD83 Antibody can refer to Human IgG2 lambda, Isotype Control (HY-P991206).
Anti-TSPAN8 Antibody is a human source antibody expressed in CHO cells, targeting TSPAN8. The Anti-TSPAN8 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TSPAN8 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MAGEA3 Antibody is a humanized antibody expressed in CHO cells that targets MAGEA3. The Anti-MAGEA3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-MAGEA3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
Atinumab (NG-101) is a CHO-expressed human antibody that targets RTN4/NOGO. Atinumab (NG-101) carries a huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Atinumab (NG-101) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-ASIC1 Antibody is a humanized antibody expressed in CHO cells that targets ASIC1. The Anti-ASIC1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Anti-ASIC1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IFNa1 Antibody is a humanized antibody expressed in CHO cells that targets IFNa1. The Anti-IFNa1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.82 kDa. The isotype control for the Anti-IFNa1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-2045 is a humanized antibody expressed in CHO cells that targets IL-4Ra/CD124. MEDI-2045 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-2045 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Nogo Receptor/NgR Antibody is a CHO-expressed human antibody targeting Nogo Receptor/NgR. The Anti-Nogo Receptor/NgR Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Nogo Receptor/NgR Antibody, you may refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SERPINE1 Antibody is a human-derived antibody expressed in CHO, targeting SERPINE1. The Anti-SERPINE1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SERPINE1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-3617 is a humanized antibody expressed in CHO cells, targeting Ang2/ANGPT2/Angiopoietin2. MEDI-3617 has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-3617 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-IL-21 Antibody is a humanized antibody expressed in CHO cells that targets IL-21. The Anti-IL-21 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.32 kDa. The isotype control for Anti-IL-21 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-INHBB/Activin B Antibody is a human antibody expressed in CHO, targeting INHBB/Activin B. The Anti-INHBB/Activin B Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-INHBB/Activin B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CAPRIN1 Antibody is a humanized antibody expressed in CHO, targeting CAPRIN1. The Anti-CAPRIN1 Antibody comes with a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CAPRIN1 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Complement Factor B Antibody is a CHO-expressed human antibody that targets Complement Factor B. The Anti-Complement Factor B Antibody carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LIF Antibody (MSC-1) is a CHO-expressed human antibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CDX-1401 is a CHO-expressed human-derived antibody targeting LY75/CD205/DEC-205. CDX-1401 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CDX-1401 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPSAB1 Antibody is a CHO-expressed human antibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
NEO-201 is a humanized antibody expressed in CHO cells that targets CEACAM6/CD66c. NEO-201 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.48 kDa. The isotype control for NEO-201 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PACAP38 Antibody is a human antibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .
Asedebart is a CHO-expressed human antibody that targets Adrenocorticotropic hormone (ACTH). Asedebart blocks the binding of ACTH to its receptor through antagonism. Asedebart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Asedebart can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Asedebart can be used for inflammatory diseases such as psoriasis and ulcerative colitis research .
Anti-AXL/UFO Antibody (ORY012) is a humanized antibody expressed in CHO cells, targeting AXL/UFO. Anti-AXL/UFO Antibody (ORY012) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.78 kDa. The isotype control for Anti-AXL/UFO Antibody (ORY012) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGF/SF Antibody (TAK-701) is a humanized antibody expressed in CHO, targeting HGF/SF. Anti-HGF/SF Antibody (TAK-701) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 153.8 kDa. The isotype control for Anti-HGF/SF Antibody (TAK-701) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Hepcidin/HAMP Antibody (LY2787106) is a CHO-expressed human antibody that targets Hepcidin/HAMP.Anti-Hepcidin/HAMP Antibody (LY2787106) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody (LY2787106) can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FGF19 Antibody (1A6) is a CHO-expressed humanized antibody that targets FGF19. Anti-FGF19 Antibody (1A6) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-FGF19 Antibody (1A6) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PAR2 Antibody (PAR650097) is a CHO-expressed human antibody that targets PAR2. Anti-PAR2 Antibody (PAR650097) has a huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 144.1 kDa. The isotype control for Anti-PAR2 Antibody (PAR650097) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PTPRC/CD45 Antibody is a CHO-expressed human antibody that targets PTPRC/CD45. Anti-PTPRC/CD45 Antibody has a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PTPRC/CD45 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL4 Antibody is a CHO expressed human antibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed human antibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Histone H2B Antibody is a CHO-expressed human antibody that targets Histone H2B. Anti-Histone H2B Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Histone H2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD20 Antibody is a humanized antibody expressed in CHO that targets CD20/MS4A1. The Anti-CD20 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD20 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-IL-20 Antibody is a Chinese hamster ovary (CHO) expressed humanized antibody that targets IL-20. The Anti-IL-20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL8 Antibody is a CHO expressed human antibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Sphingosine-1-phosphate Antibody is a humanized antibody expressed in CHO cells that targets Sphingosine-1-phosphate. Anti-Sphingosine-1-phosphate Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Sphingosine-1-phosphate Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Adakitug exhibits anti-tumor activity and can be applied in tumor research .
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CRTAM/CD355 Antibody is a humanized antibody expressed in CHO cells, targeting CRTAM/CD355. The Anti-CRTAM/CD355 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CRTAM/CD355 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (DLX212) is a CHO-expressed human antibody that targets Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (DLX212) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Amyloid Beta Antibody (DLX212) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
IMC-C103C is a human antibody expressed in CHO cells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR20 Antibody (DS-6157 antibody) is a human antibody expressed in CHO, targeting GPR20. Anti-GPR20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.62 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
LY3022859 (IMC-TR1) is a CHO-expressed human antibody that targets TBFbR2. LY3022859 (IMC-TR1) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 143 kDa. The isotype control for LY3022859 (IMC-TR1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (H2L6) is a humanized antibody expressed in CHO cells that targets IL-13. Anti-IL-13 Antibody (H2L6) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.16 kDa. The isotype control for Anti-IL-13 Antibody (H2L6) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TNFSF2/TNFa Antibody is a CHO-expressed human antibody that targets TNFSF2/TNFa. The Anti-TNFSF2/TNFa Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TNFSF2/TNFa Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MSPR/RON/CD136 Antibody is a human antibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPT2 Antibody is a CHO-expressed human antibody that targets Ang2/ANGPT2/Angiopoietin2. Anti-ANGPT2 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ANGPT2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD33 Antibody (IMGN-779 antibody) is a CHO-expressed humanized antibody targeting Siglec-3/CD33. Anti-CD33 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.6 kDa. The isotype control for Anti-CD33 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ACVR2B Antibody is a human antibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IGF-2 Antibody (DX-2647) is a CHO-expressed human antibody that targets IGF-2. Anti-IGF-2 Antibody (DX-2647) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.78 kDa. The isotype control for Anti-IGF-2 Antibody (DX-2647) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-13 Antibody (M1295) is a human-derived antibody expressed in CHO, targeting IL-13. Anti-IL-13 Antibody (M1295) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-IL-13 Antibody (M1295) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
DFRF4539A (RG-7598) is a human-derived antibody expressed in CHO that targets FcRH5/IRTA2/CD307e. DFRF4539A (RG-7598) carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DFRF4539A (RG-7598) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CHI3L1 Antibody is a human antibody expressed in CHO that targets CHI3L1. The Anti-CHI3L1 Antibody contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CHI3L1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-GPC2/Glypican 2 Antibody is a CHO-expressed human antibody that targets GPC2/Glypican 2. Anti-GPC2/Glypican 2 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-GPC2/Glypican 2 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-F8/Factor VIII Antibody is a CHO-expressed human antibody that targets F8/Factor VIII. Anti-F8/Factor VIII Antibody has a huIgG4 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-F8/Factor VIII Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PGLYRP1/PGRP-S Antibody is a CHO-expressed human antibody that targets PGLYRP1/PGRP-S. Anti-PGLYRP1/PGRP-S Antibody has huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PGLYRP1/PGRP-S Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-MPL/TPOR/CD110 Antibody (TA136) is a CHO-expressed humanized antibody that targets MPL/TPOR/CD110. The Anti-MPL/TPOR/CD110 Antibody (TA136) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-MPL/TPOR/CD110 Antibody (TA136) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RHD/CD240d Antibody is a humanized antibody expressed in CHO cells that targets RHD/CD240d. The Anti-RHD/CD240d Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-RHD/CD240d Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TM4SF1 Antibody is a CHO-expressed human antibody that targets TM4SF1. The Anti-TM4SF1 Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TM4SF1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MRC2/CD280 Antibody is a humanized antibody expressed in CHO cells, targeting MRC2/CD280. The Anti-MRC2/CD280 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for the Anti-MRC2/CD280 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CSF3R/G-CSFR Antibody is a CHO-expressed human antibody that targets CSF3R/G-CSFR. Anti-CSF3R/G-CSFR Antibody contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CSF3R/G-CSFR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TMEFF1/Tomoregulin-1 Antibody is a CHO-expressed human antibody that targets TMEFF1/Tomoregulin-1. Anti-TMEFF1/Tomoregulin-1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TMEFF1/Tomoregulin-1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR73/PROKR1 Antibody is a CHO-expressed human antibody that targets GPR73/PROKR1. Anti-GPR73/PROKR1 Antibody features a huIgG4SP heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR73/PROKR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ICAM3/CD50 Antibody is a human antibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-6/IFNb2 Antibody is a CHO-expressed human antibody that targets IL-6/IFNb2. The Anti-IL-6/IFNb2 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.46 kDa. The isotype control for Anti-IL-6/IFNb2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LY6E Antibody (MLYE4489A) (RG-7841 antibody) is a humanized antibody expressed in CHO targeting Ly6E. Anti-LY6E Antibody (MLYE4489A) contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-LY6E Antibody (MLYE4489A) can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-VCAM1/CD106 Antibody is a humanized antibody expressed in CHO cells, targeting VCAM1/CD106. The Anti-VCAM1/CD106 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.4 kDa. For the isotype control of the Anti-VCAM1/CD106 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-PROM1/CD133 Antibody is a CHO-expressed humanized antibody targeting PROM1/CD133. The Anti-PROM1/CD133 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.64 kDa. The isotype control for the Anti-PROM1/CD133 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NC-318 (5G-12) is a human-derived antibody expressed by CHO, targeting Siglec-15/CD33L3. NC-318 (5G-12) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.98 kDa. The isotype control for NC-318 (5G-12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFSF2/TNFa Antibody (hMAK195) is a human antibody expressed in CHO cells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-836 (TNX-832) is a humanized antibody expressed in CHO cells, targeting F3/Factor III/Tissue Factor/CD142. ALT-836 (TNX-832) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.34 kDa. The isotype control for ALT-836 (TNX-832) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed human antibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-BST2/CD317 Antibody is a CHO-expressed human antibody that targets BST2/CD317. The Anti-BST2/CD317 Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-BST2/CD317 Antibody can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF5/CD40 Antibody is a CHO-expressed human antibody that targets TNFRSF5/CD40. The Anti-TNFRSF5/CD40 Antibody contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-TNFRSF5/CD40 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-B7-H6/NCR3LG1 Antibody is a CHO-expressed human antibody that targets B7-H6/NCR3LG1. The Anti-B7-H6/NCR3LG1 Antibody features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa.
Anti-CYR61/CCN1 Antibody is a CHO-expressed human antibody that targets CYR61/CCN1. The Anti-CYR61/CCN1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CYR61/CCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANO1/TMEM16A Antibody is a CHO-expressed human antibody that targets ANO1/TMEM16A. The Anti-ANO1/TMEM16A Antibody consists of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-ANO1/TMEM16A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CEACAM1/CD66a Antibody is a human antibody expressed in CHO cells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CTLA-8/IL-17a Antibody is a human antibody expressed in CHO, targeting CTLA-8/IL-17a. The Anti-CTLA-8/IL-17a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTLA-8/IL-17a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed human antibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TNFRSF18/GITR/CD357 Antibody is a CHO-expressed human antibody targeting TNFRSF18/GITR/CD357. The Anti-TNFRSF18/GITR/CD357 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TNFRSF18/GITR/CD357 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Integrin a11/ITAG11 Antibody is a CHO-expressed human antibody targeting Integrin a11/ITAG11. The Anti-Integrin a11/ITAG11 Antibody is composed of huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Integrin a11/ITAG11 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-DDR1/CD167a Antibody is a CHO-expressed antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a mouse IgG1 type heavy chain and a mouse κ type light chain, with a predicted molecular weight (MW) of 143.32 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of ADCs .
Anti-PLA2G1B Antibody is a CHO-expressed human antibody that targets PLA2G1B. Anti-PLA2G1B Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PLA2G1B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. Anti-CEACAM5 Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHO cells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed human antibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHO cells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IGF1R/CD221 Antibody is a CHO-expressed human antibody that targets IGF1R/CD221. Anti-IGF1R/CD221 Antibody contains huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IGF1R/CD221 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed human antibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Integrin b7/ITGB7 Antibody is a CHO-expressed humanized antibody that targets Integrin b7/ITGB7. Anti-Integrin b7/ITGB7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Integrin b7/ITGB7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL12/SDF1a Antibody is a CHO-expressed human antibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Complement C5aR1 Antibody is a human recombinant antibody expressed in CHO cells, targeting C5AR/C5AR1 /C5R1. Anti-Complement C5aR1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-Complement C5aR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TIE2/CD202b Antibody is a CHO-expressed human antibody that targets TIE2/CD202b. Anti-TIE2/CD202b Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TIE2/CD202b Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-158P1D7 Antibody is a human-derived antibody expressed in CHO cells, targeting 158P1D7. The Anti-158P1D7 Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-158P1D7 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease .
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-SLAMF6 Antibody (h20F3ec) (SGN-CD352A antibody) is a human-derived antibody expressed in CHO targeting SLAMF6/CD352. Anti-SLAMF6 Antibody (h20F3ec) has a hulgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.29 kDa. The isotype control for Anti-SLAMF6 Antibody (h20F3ec) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CDCP1/CD318 Antibody (38 E11) is a CHO-expressed human antibody targeting CDCP1/CD318. The Anti-CDCP1/CD318 Antibody (38 E11) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CDCP1/CD318 Antibody (38 E11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CEACAM5/CEA/CD66e Antibody is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. The Anti-CEACAM5/CEA/CD66e Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5/CEA/CD66e Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Siglec-2/CD22 Antibody (NCI m971) is a humanized antibody expressed in CHO cells that targets Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (NCI m971) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.64 kDa. The isotype control for Anti-Siglec-2/CD22 Antibody (NCI m971) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ERBB1/EGFR/HER1 Antibody (7A7) is a human-derived antibody expressed in CHO cells, targeting ERBB1/EGFR/HER1. Anti-ERBB1/EGFR/HER1 Antibody (7A7) has a muIgG1 heavy chain and an mκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ERBB1/EGFR/HER1 Antibody (7A7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-2/CD22 Antibody (NCI m972) is a humanized antibody expressed in CHO, targeting Siglec-2/CD22. The Anti-Siglec-2/CD22 Antibody (NCI m972) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.3 kDa. The isotype control for Anti-Siglec-2/CD22 Antibody (NCI m972) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a CHO-expressed human antibody targeting F3/Factor III/Tissue Factor/CD142. The Anti-F3/Factor III/Tissue Factor/CD142 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-F3/Factor III/Tissue Factor/CD142 Antibody can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PDGFRB/CD140b Antibody (IMC-2C5) is a humanized antibody expressed in CHO cells that targets PDGFRB/CD140b. Anti-PDGFRB/CD140b Antibody (IMC-2C5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.54 kDa. The isotype control for Anti-PDGFRB/CD140b Antibody (IMC-2C5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Mouse IgG1 kappa, Isotype Control is a negative control reagent/isotype control for mouse-derived IgG1κ antibodies. Mouse IgG1 kappa, Isotype Control, by maintaining the same immunoglobulin structure (including isotype, light chain, etc.) as the specific mouse IgG1κ subtype primary antibody, eliminates false positive signals caused by non-specific binding in immunological experiments, thus playing a core role in verifying the specificity of the experiment. Mouse IgG1 kappa, Isotype Control can be applied to immunolocalization experiments in the field of cell biology, such as immunofluorescence staining and immunohistochemistry, assisting in research on protein subcellular localization and cell structure analysis, ensuring the reliability of experimental results .
The Anti-GPR44/PTGDR2/CD294 Antibody is a human antibody expressed in CHO cells that targets GPR44/PTGDR2/CD294. The Anti-GPR44/PTGDR2/CD294 Antibody is equipped with an huIgG1 heavy chain and an huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GPR44/PTGDR2/CD294 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-B7-H4/VTCN1 Antibody is a CHO-expressed human antibody that targets B7-H4/VTCN1. The Anti-B7-H4/VTCN1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H4/VTCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KIR2DL1/CD158a Antibody is a CHO-expressed human antibody that targets KIR2DL1/CD158a. The Anti-KIR2DL1/CD158a Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KIR2DL1/CD158a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Mouse IgG2a kappa, Isotype Control is a negative control reagent/isotype control for mouse-derived IgG2aκ antibodies. Mouse IgG2a kappa, Isotype Control maintains the same immunoglobulin structure (including isotype, light chain, etc.) as the specific mouse IgG2aκ subtype primary antibody, thus eliminating false positive signals caused by non-specific adsorption in immunological experiments and playing a core role in verifying experimental specificity. Mouse IgG2a kappa, Isotype Control can be applied to immunolocalization experiments such as immunofluorescence staining and immunohistochemistry in the field of cell biology, assisting in protein subcellular localization, cell structure analysis, and other research to ensure the reliability of experimental results .
Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized antibody expressed in CHO cells, targeting ENPP3/CD203c. Anti-ENPP3/CD203c Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 154.04 kDa. The isotype control for Anti-ENPP3/CD203c Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Rat IgG2a kappa, Isotype Control is a monoclonal antibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology. Rat IgG2a kappa, an isotype control, can be used as an isotype control for Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144), Anti-Mouse CD11a/LFA-1α Antibody (M17/4) (HY-P990801), and Anti-Mouse IL-2 Antibody (S4B6-1) (HY-P990796) .
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .
Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC50s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch .
Stellettamide A TFA is a marine toxin found in a marine sponge. Stellettamide A TFA is a calmodulin inhibitor. Stellettamide A TFA can inhibit Ca 2+/Mg 2+ ATPase, phosphodiesterase, myosin light chain , and Mg 2+-ATPase. Stellettamide A TFA inhibits high K +- and Ca 2+-induced contraction in permeabilized smooth muscle. Stellettamide A TFA exhibits antifungal activity against Mortierella remannianus. Stellettamide A TFA can be used for the research of fungal infection .
Ferritin light chain/FTL protein is pivotal in iron homeostasis, storing iron in a soluble, non-toxic form and delivering it to cells. In kidney development, FTL mediates iron uptake in capsule cells, crucial for organogenesis. Structurally, FTL, an oligomer with light and heavy subunits forming a spherical shell, facilitates iron entry through pores. Mutations in the C-terminus disrupt pore formation, impacting iron accumulation. Ferritin light chain/FTL Protein, Human (His) is the recombinant human-derived Ferritin light chain/FTL protein, expressed by E. coli , with N-6*His labeled tag.
Neurotoxin light chain protein is a component of botulinum toxin that induces flaccid paralysis by inhibiting the release of acetylcholine in the nervous system. As the precursor of botulinum neurotoxin E, it uses polysialylated gangliosides and membrane-anchored proteins as coreceptors. Neurotoxin Type E Light Chain Protein, Botulinum (His, Myc) is the recombinant Neurotoxin Type E Light Chain protein, expressed by E. coli , with N-His labeled and C-Myc labeled tag.
Type neurotoxin light chain protein is an important component of botulinum toxin that induces paralysis by blocking the release of acetylcholine in the host nervous system. As the precursor of botulinum neurotoxin B, it uses polysialylated gangliosides and membrane-anchored proteins as coreceptors. Neurotoxin Type B Light Chain Protein, Botulinum (P. pastoris, His) is the recombinant Neurotoxin Type B Light Chain protein, expressed by P. pastoris , with N-His labeled tag.
PIN/DYNLL1 acts as a non-catalytic accessory component in the cytoplasmic dynein 1 complex, connecting dynein to cargos and adapter proteins for dynein modulation. It functions as a motor for retrograde vesicle movement along microtubules, potentially influencing cytoskeletal structure. PIN/DYNLL1 enhances ESR1 transactivation and aids ESR1 nuclear localization. PIN/DYNLL1 Protein, Human (His) is the recombinant human-derived PIN/DYNLL1 protein, expressed by E. coli , with N-6*His labeled tag.
Neurotoxin light chain protein is a component of botulinum toxin that induces flaccid paralysis by disrupting the release of acetylcholine in the nervous system. This precursor relies on polysialylated gangliosides and membrane-anchored proteins as coreceptors. Neurotoxin Type A Light Chain Protein, Botulinum (P. pastoris, His) is the recombinant Neurotoxin Type A Light Chain protein, expressed by P. pastoris , with N-6*His labeled tag.
Plasminogen protein is the key precursor of plasmin and plays a central role in a variety of physiological and pathological processes. Plasmin is derived from plasminogen and dissolves fibrin during blood coagulation, affecting embryonic development, tissue remodeling, tumor invasion and inflammation. Plasminogen Protein, Human is the recombinant human-derived Plasminogen protein, expressed by E. coli , with tag free.
The KLC2 protein is a key kinesin-1 complex component that is essential for the generation of microtubule-associated forces and organelle transport. Its light chain facilitates the coupling of cargo to the heavy chain and regulates ATPase activity. KLC2 Protein, Human (sf9, His-GST) is the recombinant human-derived KLC2 protein, expressed by Sf9 insect cells , with C-His, N-GST labeled tag.
MAP1LC3B is a key ubiquitin-like modifier essential for the formation of autophagosome vacuoles, which maintains cellular homeostasis. In mitophagy, it regulates mitochondrial number, suppresses reactive oxygen species and ensures energy efficiency. MAP1LC3B Protein, Human is the recombinant human-derived MAP1LC3B protein, expressed by E. coli , with tag free.
MAP1LC3A is a key ubiquitin-like modifier essential for autophagosome vacuole formation, ensuring cellular homeostasis. As part of the GABARAP/GATE-16 subfamily, it plays a crucial role in late autophagosome maturation. MAP1LC3A Protein, Human (His) is the recombinant human-derived MAP1LC3A protein, expressed by E. coli , with C-6*His labeled tag.
MAP1LC3B is a key ubiquitin-like modifier essential for the formation of autophagosome vacuoles, which maintains cellular homeostasis. In mitophagy, it regulates mitochondrial number, suppresses reactive oxygen species and ensures energy efficiency. MAP1LC3B Protein, Human (His) is the recombinant human-derived MAP1LC3B protein, expressed by E. coli , with C-His.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XI/F11 protein, expressed by HEK293 , with C-His labeled tag.
S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (N-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with N-6*His labeled tag.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (His) is the recombinant pig-derived Coagulation Factor XII/F12 protein, expressed by E. coli , with N-6*His labeled tag.
S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (sf9, His) is the recombinant human-derived S100A8 protein, expressed by Sf9 insect cells , with C-His labeled tag.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (P. pastoris, His) is the recombinant pig-derived F12/Coagulation Factor XII, Pig, expressed by P. pastoris , with N-6*His labeled tag.
Factor IX (F9) is a vitamin K-dependent plasma protein that plays a critical role in the intrinsic pathway of coagulation. Factor IX coordinates the conversion of factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation factor IX/F9 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor IX/F9 protein, expressed by HEK293 , with C-6*His labeled tag.
S100A8 protein functions as a danger signal in inflammation, activating innate immune cells by binding to receptors like Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). This triggers signaling pathways that enhance the pro-inflammatory response. S100A8 Protein, Rat (His) is the recombinant rat-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag.
Tofersen-d27 (BIIB067-d27) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.
MPO light chain/Myeloperoxidase Antibody (YA9530) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to MPO light chain/Myeloperoxidase.
Myosin light chain kinase/MLCK Antibody (YA277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Myosin light chain kinase/MLCK.
Myosin light chain kinase/MLCK Antibody (YA3133) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Myosin light chain kinase/MLCK.
Dynein Light Chain Tctex Type 1 Antibody (YA3263) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Dynein Light Chain Tctex Type 1.
Dynein Light Chain Tctex Type 1 Antibody (YA3263) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Dynein Light Chain Tctex Type 1.
Myosin light chain kinase/MLCK Antibody (YA4295) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Myosin light chain kinase/MLCK.
Myosin light chain kinase/MLCK Antibody (YA4295) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Myosin light chain kinase/MLCK.
Constant region of lambda light chains antibody; Ig lambda chain C regions antibody; IGLC antibody; Immunoglobulin lambda constant 1 antibody; Mcg marker antibody;
WB, ICC/IF, IHC-P, FC
Human
Lambda Light Chain Antibody (YA6642) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lambda Light Chain.
NFKBIA; Inhibitor of KB alpha; I kappa B alpha; I(Kappa)B(alpha); IkappaBalpha; IKBA; IKBalpha; MAD 3; MAD3; Major histocompatibility complex enhancer binding protein MAD3; NF kappa B inhibitor alpha; NFKBI; NFKBIA; Nuclear factor of kappa light chain gene enhancer in B cells; Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha; IKBA_HUMAN.
WB, IHC-P, IHC-F, IF-Tissue, ICC/IF
Human, Rat
IKB alpha Antibody (YA6438) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IKB alpha.
NFKBIA; Inhibitor of KB alpha; I kappa B alpha; I(Kappa)B(alpha); IkappaBalpha; IKBA; IKBalpha; MAD 3; MAD3; Major histocompatibility complex enhancer binding protein MAD3; NF kappa B inhibitor alpha; NFKBI; NFKBIA; Nuclear factor of kappa light chain gene enhancer in B cells; Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha; IKBA_HUMAN.
WB, IHC-P, IHC-F, IF-Tissue, ICC/IF
Human, Rat
IKB alpha Antibody (YA6438) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IKB alpha.
Immunoglobulin kappa variable 1D-16 Ig kappa chain V-I region HK146 Ig kappa chain V-I region HK189 Immunoglobulin kappa constant Ig kappa chain C regionCurated Ig kappa chain C region AG Ig kappa chain C region CUM Ig kappa chain C region EU Ig kappa chain C region OU Ig kappa chain C region ROY Immunoglobulin kappa variable 1D-16 Ig kappa chain V-I region HK146 Ig kappa chain V-I region HK189 Immunoglobulin kappa constant Ig kappa chain C regionCurated Ig kappa chain C region AG Ig kappa chain C region CUM Ig kappa chain C region EU Ig kappa chain C region OU Ig kappa chain C region ROY Ig kappa chain C region TI
WB, IHC-P
Human
Human Kappa light chain Antibody (YA6604) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Human Kappa light chain.
Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
Tofersen-d27 (BIIB067-d27) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
